版權(quán)說(shuō)明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
1、Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes Gde, P., Lund-Anderen, H., Hans-Henrik, P., and O. PedersenN Engl J Med 2008;358:580-91Peter KarackiGIM Journal ClubMarch 25, 2008Diabetes BackgroundIn 2005, U.S. prevalence of DM = 20.8 million people or 7% of the population6th
2、 leading cause of death in the U.S. in 2004Risk of death is 2x for an individual with diabetes vs. one without it at the same ageFrom 1991 to 2001, the CDC found a 61% increase in diagnosis of diabetesDiabetes ComplicationsHeart Disease 2-4x death rates vs. adults w/o DMCVA risk = 2-4x higher vs. ad
3、ults w/o DMRetinopathy #1 cause of blindness in adults 20-74 yoa.Nephropathy #1 cause of CRFNervous system damageAcute hypoglycemia or hyperglycemiaPeripheral vascular diseaseComplications during pregnancySteno-2 Study: Intensive therapy vs. conventional therapy for DMII (2003)Intensive therapyBenef
4、its: (n = 80)Hazard ratioConfidence Interval1. CV Disease0.470.24 to 0.732. Nephropathy0.390.17 to 0.873. Retinopathy0.420.21 to 0.864. Autonomic neuropathy0.370.18 to 0.79Gde et al. Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes. NEJM. 2003;348:383-393Steno-
5、2 Follow-up: Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes (2008)Steno-2 mean length = 7.8 yrs Steno-2 f/u mean length = +5.5 yrs“Where are they now?”Study PopulationEnd of Steno II Beginning of f/uSteno IISteno-II Treatment ObjectivesGde et al. Multifactorial Intervention
6、and Cardiovascular Disease in Patients with Type 2 Diabetes. NEJM. 2003;348:383-393Steno-II f/u goals for both groupsSteno-II Intensive Therapy (cont)If HTN thiazide, CCBs, BB, or ACE-I/ARBDaily MVI Vit. C, D-tocopherol, folic acid, + chrome picolinateFat 30% of daily calorie intake (saturated 10%)L
7、ight-to-mod. exercise x 30 min 3-5x/week encouragedSmokers or smoking spouses smoking cessation classesSteno-II f/u Endpoints2 Endpoints1. Death from a CV cause2. CVD events: a. nonfatal CVA b. nonfatal MI c. CABG d. PCI/PVD int. e. amputation 3 Endpoints1. Incident nephropathy2. Development/progres
8、sion: a. Diabetic retinopathy b. Peripheral neuropathy c. Autonomic neuropathy1 Endpoint = Time to death from any causeStatistical AnalysisStatistical analysis to begin when 60 patients or of a group had died1/2 Outcomes 1. Kaplan-Meier time to 1st event 2. Treatments compared by log-rank test 3. Pr
9、oportion-hazards model to generate hazard ratios + CIs3 Outcomes Proportional-hazards model w/adjustment for age, duration of diabetes, sex + microvascular status at baseline to determine relative risksChanges in measured values 1. Analysis of covariance2. Mann-Whitney testClinical Characteristics (
10、cont)Fig. 2A Changes in Selected Risk factors during the Interventional study and Follow-up Period7.71.2/8.01.414734/1553214014/146187129/7728748/73799 (29-1148)148 (35-318)Intensive therapyConventional therapy1 Endpoint: Cumulative Incidence of DeathFig. 3A Cumulative risk of death from any causeIn
11、tensive Group: 24 deaths (30%)Conventional Group: 40 deaths (50%)ARR = 20% (P=0.02)Hazard ratio = 0.5495% CI = 0.32 to 0.89 (P=0.02) 2 Endpoints: Number of CVD eventsFig. 3C Number of deaths from a CV cause and number of CVD eventsNumber of CVD EventsIntensive Group: 51 events in 25 patients (31%) o
12、r 0.6/PatientConventional Group: 158 events in 48 patients (60%) or 2.0/patientARR = 29%Hazard ratio = 0.4195% CI = 0.25 to 0.67 (P=0.001) 3 Endpoints: Microvascular Complications20/37RR = 0.44 (P=0.004) 95% CI = 0.25 0.77RR = 0.57 (P=0.01) 95% CI = 0.37 0.8841/5439/52RR = 0.53 (P=0.004) 95% CI = 0.
13、34 0.8144/46RR = 0.97 (P=0.89) 95% CI = 0.62 1.511 Endpoint 30% death rate in intensive therapy group vs. 50% in the conventional group over 13.3 years (ARR = 20%, P = 0.02).Discussion2 Endpoints 51 CV events in 25 patients in the intensive-therapy group vs. 158 in 48 patients in the conventional gr
14、oup = a mean of 0.6 events per patient vs. 2.0, respectively. (ARR = 29%). 3 Endpoints Statistically significant in progression of nephropathy, retinopathy, and autonomic neuropathy in intensive-therapy group. No in progression of diabetic neuropathy.Clinical characteristics Fewer differences in ris
15、k factors in the f/u study vs. the original one. Excellent LDL values obtained. Mediocre HbA1c values and poor SBP control. 1. Length of the studyStrengths2. Excellent retention of patients given the study duration3. Comprehensiveness of the study in terms of measuring multiple outcomes and complica
16、tions of diabetes4. The majority of the outcome measures reached statistical significanceWeaknesses/Limitations1. The patient population only included white Danes3. The therapies received by the conventional group were ill-defined and inconsistent versus the intensive-therapy group 2. The overall sa
17、mple size of 160 is relatively small4. NPH and regular insulin are arguably inferior to glargine and ultra-short acting insulins in terms of risk of complications and stable management of blood glucose5. Further data analysis should have been done to determine if individual risk factors (such as SBP
18、 or LDL) had a statistical effect on the different measured outcomesImpact on Clinical Practice4. 2008 ADA Diabetes Treatment Goals1. Diabetes management is not just fixing BG2. The intensive therapy group benefited from constant education (4x a year during Steno 2) that likely has an immeasurable i
19、mpact on their outcomes in complications of diabetes 3. It appears as if many diabetics “forget” what they have learned over time.ReferencesGde, P., Lund-Anderen, H., Hans-Henrik, P., and O. Pedersen. Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes. NEJM. 2008;358:580-912005 National Diabetes Fact Sheet, CDCMinino, A., Heron, M., Murphy, S., and K. Kochanek. Deaths: Final Data for 2004. CDC National Vitals Statistics Report. 2004;55;19 Mokdad, A., Bowman, B., Ford, E., Vi
溫馨提示
- 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 小麥加工中的食品安全風(fēng)險(xiǎn)傳播與防控考核試卷
- 廚房用金屬表面處理技術(shù)考核試卷
- 簡(jiǎn)單校時(shí)系統(tǒng)課程設(shè)計(jì)
- 食品安全營(yíng)養(yǎng)課程設(shè)計(jì)
- 課程設(shè)計(jì)帶有上下位機(jī)
- 數(shù)字信號(hào)課程設(shè)計(jì)音樂(lè)
- 貴陽(yáng)市兒童運(yùn)動(dòng)課程設(shè)計(jì)
- 工廠電控課程設(shè)計(jì)書
- 聯(lián)動(dòng)凸輪課程設(shè)計(jì)
- linux操作系統(tǒng)課程設(shè)計(jì)
- DB32T 3904-2020 電動(dòng)自行車停放充電場(chǎng)所消防技術(shù)規(guī)范
- 人教PEP版四年級(jí)英語(yǔ)上冊(cè)《Unit2-A-Lets-spell優(yōu)質(zhì)課件》
- 網(wǎng)絡(luò)傳播概論教案
- 西方歌劇-課件
- EORTC-QLQ-C30-(version-3)-生活質(zhì)量調(diào)查問(wèn)卷
- 管理層的財(cái)務(wù)思維課件
- 煤炭建設(shè)井巷工程消耗量定額(2015除稅基價(jià))總說(shuō)明及章說(shuō)明
- 《氣候特征的比較》課件
- 英語(yǔ)論文分析學(xué)習(xí)-第2節(jié)-literature-review課件
- 調(diào)壓箱、調(diào)壓柜維護(hù)保養(yǎng)標(biāo)準(zhǔn)
- 國(guó)中學(xué)生物理競(jìng)賽實(shí)驗(yàn)指導(dǎo)書思考題參考答案
評(píng)論
0/150
提交評(píng)論